(18:37 GMT) Revolution Medicines Price Target Raised to $181.00/Share From $165.00 by Wedbush
DO Dow Jones Newswires Revolution Medicines Is Maintained at Outperform by Wedbush 7/3/2026, 02:37 AM GMT+8 Dow Jones Newswires RV RVMD (18:37 GMT) Revolution Medicines Price Target Raised to $181.00/Share From $165.00 by Wedbush Market News Dow Jones Newswires Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results GlobeNewswire Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Dow Jones Newswires Revolution Medicines Is Maintained at Buy by Truist Securities Dow Jones Newswires Revolution Medicines Is Maintained at Buy by Needham
